FP
ICPT

Fiduciary Planning’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Fiduciary Planning’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-110
Closed -$3K – 284
2021
Q1 		$3K Hold
110
– – ﹤0.01% 225
2020
Q4 		$3K Hold
110
– – ﹤0.01% 203
2020
Q3 		$5K Buy
+110
New +$5.05K 0.01% 145

Other funds holding ICPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Fiduciary Planning's ICPT Position: Q2 2021 in Review

Fiduciary Planning sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q2 2021, closing a stake of 110 shares — an estimated $3K sold.

Fiduciary Planning first reported a position in ICPT in Q3 2020 and held it in 3 quarters. The position peaked at $5K in Q3 2020. 129 funds tracked by Wall St. Rank hold ICPT as of Q2 2021.

  • Fiduciary Planning reported no remaining Intercept Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
  • Fiduciary Planning sold 110 Intercept Pharmaceuticals, Inc. shares in Q2 2021, an estimated $3K.
  • Fiduciary Planning first reported a position in Intercept Pharmaceuticals, Inc. in Q3 2020 and held it in 3 quarters.
  • Fiduciary Planning's Intercept Pharmaceuticals, Inc. position peaked at $5K in Q3 2020.
  • 129 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q2 2021.

Based on Fiduciary Planning's 13F filing for Q2 2021, filed 6 Aug 2021.